Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 591-598

  Alkema, N G ^a   Tomar, T ^a   Van Der Zee, A G J ^a   Everts, M ^a   Meersma, G J ^a   Hollema, H ^a   De Jong, S ^a   Van Vugt, M A T M ^a   Wisman, G B A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemoresistance; Chk2; DNA damage response; Ovarian cancer; Platinum based chemotherapy

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; CISPLATIN; DNA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TREATMENT RESPONSE;

CHEMORESISTANCE; CHK2; DNA DAMAGE RESPONSE; OVARIAN CANCER; PLATINUM-BASED CHEMOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CHECKPOINT KINASE 2; CISPLATIN; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901687762     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.557     Document Type: Article

References (40)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics, 2012 CA Cancer J Clin 62 1 Jan-Feb 2012 10 29
2. P.J. McHugh, V.J. Spanswick, and J.A. Hartley Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance Lancet Oncol 2 8 Aug 2001 483 490
3. T. Bessho Induction of DNA replication-mediated double strand breaks by psoralen DNA interstrand cross-links J Biol Chem 278 7 Feb 14 2003 5250 5254
4. J. Bartek, and J. Lukas Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell 3 5 May 2003 421 429
5. Y. Pereg, S. Lam, A. Teunisse, S. Biton, E. Meulmeester, and L. Mittelman et al. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage Mol Cell Biol 26 18 Sep 2006 6819 6831
6. M.B. Kastan, and J. Bartek Cell-cycle checkpoints and cancer Nature 432 7015 Nov 18 2004 316 323
7. C.J. Lord, M.D. Garrett, and A. Ashworth Targeting the double-strand DNA break repair pathway as a therapeutic strategy Clin Cancer Res 12 15 Aug 1 2006 4463 4468
8. L.P. Martin, T.C. Hamilton, and R.J. Schilder Platinum resistance: the role of DNA repair pathways Clin Cancer Res 14 5 Mar 1 2008 1291 1295
9. E. Bolderson, D.J. Richard, B.B. Zhou, and K.K. Khanna Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair Clin Cancer Res 15 20 Oct 15 2009 6314 6320
10. A.G. Jobson, G.T. Lountos, P.L. Lorenzi, J. Llamas, J. Connelly, and D. Cerna et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}- amide] J Pharmacol Exp Ther 331 3 Dec 2009 816 826
11. L. Carlessi, G. Buscemi, G. Larson, Z. Hong, J.Z. Wu, and D. Delia Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 Mol Cancer Ther 6 3 Mar 2007 935 944
12. V.E. Anderson, M.I. Walton, P.D. Eve, K.J. Boxall, L. Antoni, and J.J. Caldwell et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors Cancer Res 71 2 Jan 15 2011 463 472
13. H. Vakifahmetoglu, M. Olsson, C. Tamm, N. Heidari, S. Orrenius, and B. Zhivotovsky DNA damage induces two distinct modes of cell death in ovarian carcinomas Cell Death Differ 15 3 Mar 2008 555 566
14. J. Kang, A.D. D'Andrea, and D. Kozono A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy J Natl Cancer Inst 104 9 May 2 2012 670 681
15. M. Ganzinelli, P. Mariani, D. Cattaneo, R. Fossati, R. Fruscio, and S. Corso et al. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations Eur J Cancer 47 7 May 2011 1086 1094
16. P. de Graeff, J. Hall, A.P. Crijns, G.H. de Bock, J. Paul, and K.A. Oien et al. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies Br J Cancer 95 5 Sep 4 2006 627 633
17. F. Roossink, H.W. Wieringa, M.G. Noordhuis, K.A. ten Hoor, M. Kok, and L. Slagter-Menkema et al. The role of ATM and 53BP1 as predictive markers in cervical cancer Int J Cancer 131 9 Nov 1 2012 2056 2066
18. N. Leffers, M.J. Gooden, A.A. Mokhova, W.M. Kast, H.M. Boezen, and K.A. Ten Hoor et al. Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer Gynecol Oncol 113 2 May 2009 256 263
19. D.J. Ruiter, C.M. Ferrier, G.N. van Muijen, S.C. Henzen-Logmans, S. Kennedy, and M.D. Kramer et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis Eur J Cancer 34 9 Aug 1998 1334 1340
20. M.A. van Vugt, A.K. Gardino, R. Linding, G.J. Ostheimer, H.C. Reinhardt, and S.E. Ong et al. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint PLoS Biol 8 1 Jan 2010 e1000287
21. J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort, and K. Zieger et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 7035 Apr 14 2005 864 870
22. Y. Ariumi, M. Kuroki, H. Dansako, K. Abe, M. Ikeda, and T. Wakita et al. The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication J Virol 82 19 Oct 2008 9639 9646
23. V.G. Gorgoulis, L.V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, and T. Liloglou et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions Nature 434 7035 Apr 14 2005 907 913
24. R.A. DiTullio Jr., T.A. Mochan, M. Venere, J. Bartkova, M. Sehested, and J. Bartek et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer Nat Cell Biol 4 12 Dec 2002 998 1002
25. H.R. Mirshahidi, J. Rogers, R. Tallaksen, M. Szwerc, and P. Zhang CHK-2 expression in lung cancer and tumor sensitivity to DNA damage-inducing therapy ASCO Annual Meeting Proceedings Journal of Clinical Oncology 23(16S) 2005 724
26. J. Agner, J. Falck, J. Lukas, and J. Bartek Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway Exp Cell Res 302 2 Jan 15 2005 162 169
27. J. Falck, N. Mailand, R.G. Syljuasen, J. Bartek, and J. Lukas The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis Nature 410 6830 Apr 12 2001 842 847
28. P. Zhang, J. Wang, W. Gao, B.Z. Yuan, J. Rogers, and E. Reed CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer Mol Cancer 3 May 4 2004 14
29. O. Kilpivaara, J. Bartkova, H. Eerola, K. Syrjakoski, P. Vahteristo, and J. Lukas et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients Int J Cancer 113 4 Feb 10 2005 575 580
30. A. Sullivan, M. Yuille, C. Repellin, A. Reddy, O. Reelfs, and A. Bell et al. Concomitant inactivation of p53 and Chk2 in breast cancer Oncogene 21 9 Feb 21 2002 1316 1324
31. M. Sarbia, N. Ott, F. Puhringer-Oppermann, and B.L. Brucher The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus Br J Cancer 97 10 Nov 19 2007 1404 1408
32. L. Antoni, N. Sodha, I. Collins, and M.D. Garrett CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 7 12 Dec 2007 925 936
33. H. Itamochi, M. Nishimura, N. Oumi, M. Kato, T. Oishi, and M. Shimada et al. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary Int J Gynecol Cancer 24 1 Jan 2014 61 69
34. R.J. Kurman, and Ie M. Shih The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am J Surg Pathol 34 3 Mar 2010 433 443
35. N. Pabla, S. Huang, Q.S. Mi, R. Daniel, and Z. Dong ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis J Biol Chem 283 10 Mar 7 2008 6572 6583
36. I.M. Pires, T.H. Ward, and C. Dive Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors Br J Pharmacol 159 6 Mar 2010 1326 1338
37. P. Zhang, W. Gao, H. Li, E. Reed, and F. Chen Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells Biochem Biophys Res Commun 328 2 Mar 11 2005 567 572
38. S. Ashwell, and S. Zabludoff DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy Clin Cancer Res 14 13 Jul 1 2008 4032 4037
39. B.B. Zhou, and J. Bartek Targeting the checkpoint kinases: chemosensitization versus chemoprotection Nat Rev Cancer 4 3 Mar 2004 216 225
40. H. Jiang, J.R. Pritchard, R.T. Williams, D.A. Lauffenburger, and M.T. Hemann A mammalian functional-genetic approach to characterizing cancer therapeutics Nat Chem Biol 7 2 Feb 2011 92 100